Valeur202020212022202320242025Total du passif2.39 B3.06 B3.7 B4.05 B4.17 B4.18 BTotal des capitaux propres1.02 B588.2 M-158.22 M-220.64 M67.09 M789.18 MTotal du passif et des capitaux propres3.41 B3.64 B3.55 B3.83 B4.24 B4.97 BDette totale191.28 M675.7 M1.02 B1.02 B1.02 B1.01 BDette nette-1.68 B-1.76 B-1.18 B-1.42 B-1.67 B-1.9 B
Alnylam Pharmaceuticals, Inc. - Common Stock
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.